Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 20/20 | 0.58 |
| ▸ | CTSL | P07711 | 9/20 | 0.58 |
| ▸ | CTSS | P25774 | 9/20 | 0.58 |
| ▸ | CTSK | P43235 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4982266 | 1.00 | CTSB (0.58) | CTSBCTSLCTSSCTSK | |
| Hydrochloric Acid SCHEMBL4980175 | 0.99 | CTSB (0.58) | CTSBCTSLCTSSCTSK | |
| Hydrochloric Acid SCHEMBL6809685 | 0.99 | CTSB (0.58) | CTSBCTSLCTSSCTSK | |
| SCHEMBL4982267 | 0.87 | CTSB (0.54) | CTSBCTSLCTSSCTSK | |
| Hydrochloric Acid SCHEMBL4980180 | 0.86 | CTSB (0.54) | CTSBCTSLCTSSCTSK | |
| SCHEMBL6213718 | 0.81 | CTSB (0.47) | CTSBCTSLCTSSCTSK | |
| SCHEMBL6218326 | 0.81 | CTSB (0.47) | CTSBCTSLCTSSCTSK | |
| SCHEMBL6217373 | 0.81 | CTSB (0.46) | CTSBCTSLCTSSCTSK | |
| SCHEMBL6214227 | 0.79 | CTSB (0.47) | CTSBCTSLCTSSCTSK | |
| SCHEMBL4978315 | 0.79 | SLC7A5 (0.41) | CTSBCTSLCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080027060-A1 | DIPEPTIDE NITRILES | ALTMANN EVA | 2008-01-31 | — | — | US | disclosed |
| US-20060235220-A1 | Dipeptide nitriles | MISSBACH MARTIN | 2006-10-19 | — | — | US | disclosed |
| EP-1283825-B1 | N-SUBSTITUTED PEPTIDYL NITRILES AS CYSTEINE CATHEPSIN INHIBITORS | NOVARTIS AG (CH) | 2005-09-14 | — | — | EP | disclosed |
| US-6812237-B2 | (ARYLAMINOACEAMIDO)ACETONITRILE DERIVATIVES | NOVARTIS AG (CH) | 2004-11-02 | — | — | US | disclosed |
| US-20040110806-A1 | Dipeptide derivatives | ALTMANN EVA (CH) | 2004-06-10 | — | — | US | disclosed |
| US-20040029814-A1 | Dipeptide nitriles | ALTMANN EVA (CH) | 2004-02-12 | — | — | US | disclosed |
| US-20030158256-A1 | N-substituted peptidyl nitriles as cysteine cathepsin inhibitors | NOVARTIS AG (CH) | 2003-08-21 | — | — | US | disclosed |
| EP-1283825-A1 | N-SUBSTITUTED PEPTIDYL NITRILES AS CYSTEINE CATHEPSIN INHIBITORS | Novartis AG (CH) | 2003-02-19 | — | — | EP | disclosed |
| US-6353017-B1 | INHIBITORS OF CATHESPINS USING DIPEPTIDE NITRILES AS ANTIINFLAMMATORY AGENTS AND ANTIARTHRITIC AGENTS | NOVARTIS AG (CH) | 2002-03-05 | — | — | US | disclosed |
| WO-2001087828-A1 | N-SUBSTITUTED PEPTIDYL NITRILES AS CYSTEINE CATHEPSIN INHIBITORS | NOVARTIS AG (CH) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110806-A1 | Dipeptide derivatives | CTSL, CTSZ, CTSS | CTSB 5/4885CTSL 1/4885CTSS 3/4885 |
| US-20030158256-A1 | N-substituted peptidyl nitriles as cysteine cathepsin inhibitors | CTSS, CTSV, CTSF | CTSB 4/4885CTSL 9/4885CTSS 1/4885 |
| US-20040029814-A1 | Dipeptide nitriles | NOS1, CTSL, CTSS | CTSB 5/4885CTSL 2/4885CTSS 3/4885 |
| US-20060235220-A1 | Dipeptide nitriles | CTSL, CTSS, CTSB | CTSB 3/4885CTSL 1/4885CTSS 2/4885 |
| US-20080027060-A1 | DIPEPTIDE NITRILES | CTSL, CTSS, CTSB | CTSB 3/4885CTSL 1/4885CTSS 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.